Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 260

The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.

A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1–insensitive models of triple-negative breast cancer

Open access
Cheng, Ning, Watkins-Schulz, Rebekah, Junkins, Robert D., David, Clément N., Johnson, Brandon M., Montgomery, Stephanie A., Peine, Kevin J., Darr, David B., Yuan, Hong, McKinnon, Karen P., Liu, Qi, Miao, Lei, Huang, Leaf, Bachelder, Eric M., Ainslie, Kristy M., Ting, Jenny P-Y · 2018 · JCI Insight

Abstract

Triple-negative breast cancer (TNBC) has few therapeutic options, and alternative approaches are urgently needed. Stimulator of IFN genes (STING) is becoming an exciting target for therapeutic adjuvants. However, STING resides inside the cell, and the intracellular delivery of CDNs, such as cGAMP, is required for the optimal activation of STING. We show that liposomal nanoparticle-delivered cGAMP (cGAMP-NP) activates STING more effectively than soluble cGAMP. These particles induce innate and adaptive host immune responses to preexisting tumors in both orthotopic and genetically engineered models of basal-like TNBC. cGAMP-NPs also reduce melanoma tumor load, with limited responsivity to anti-PD-L1. Within the tumor microenvironment, cGAMP-NPs direct both mouse and human macrophages (M), reprograming from protumorigenic M2-like phenotype toward M1-like phenotype; enhance MHC and costimulatory molecule expression; reduce M2 biomarkers; increase IFN-γ-producing T cells; augment tumor apoptosis; and increase CD4+ and CD8+ T cell infiltration. Activated T cells are required for tumor suppression, as their depletion reduces antitumor activity. Importantly, cGAMP-NPs prevent the formation of secondary tumors, and a single dose is sufficient to inhibit TNBC. These data suggest that a minimal system comprised of cGAMP-NP alone is sufficient to modulate the tumor microenvironment to effectively control PD-L1-insensitive TNBC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci.insight.120638

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 63 references

Cited by

See all 260

Metadata

Authors
Cheng, N., Watkins-Schulz, R., Junkins, R. D., David, C. N., Johnson, B. M., Montgomery, S. A., Peine, K. J., Darr, D. B., Yuan, H., McKinnon, K. P., Liu, Q., Miao, L., Huang, L., Bachelder, E. M., Ainslie, K. M., & Ting, J. P.-Y.
Venue
JCI Insight
Published
2018-11-15
Volume
3
Issue
22
ISSN
2379-3708 (ISSN-L)
OpenAlex
W2901307735
Cited by
260
References
63
FWCI
9.42
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1–insensitive models of triple-negative breast cancer. https://app.cochat.ai/papers/10.1172/jci.insight.120638
The paper
Cheng, N., Watkins-Schulz, R., Junkins, R. D., David, C. N., Johnson, B. M., Montgomery, S. A., Peine, K. J., Darr, D. B., Yuan, H., McKinnon, K. P., Liu, Q., Miao, L., Huang, L., Bachelder, E. M., Ainslie, K. M., & Ting, J. P.-Y. (2018). A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1–insensitive models of triple-negative breast cancer. JCI Insight. https://doi.org/10.1172/jci.insight.120638

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.